Moderna Inc.'s (MRNA) stock soared 5.11% in after-hours trading on Friday following news that the company secured a $590 million award from the U.S. Department of Health and Human Services (HHS) to accelerate the development of its mRNA-based pandemic influenza vaccines.
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, including Moderna's investigational pandemic influenza vaccine candidate, mRNA-1018. The agreement will also fund the expansion of clinical studies for up to five additional subtypes of pandemic influenza, such as the H5N1 avian flu virus.
Moderna initiated a Phase 1/2 study in 2023 to evaluate the safety and immunogenicity of mRNA-1018 in healthy adults, including vaccine candidates against H5 and H7 avian influenza viruses. Based on positive preliminary data from this study, the company is now preparing to advance mRNA-1018 into a Phase 3 trial.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。